Mumbai: Piramal Pharma Solutions, the CDMO division of Piramal Pharma Ltd. (NSE: PPLPHARMA, BSE: 543635), has initiated a transformative $90 million expansion across its U.S. facilities to accelerate its integrated offerings in sterile injectables and antibody-drug conjugates (ADCs).
This strategic move reinforces the company’s leadership in end-to-end pharmaceutical manufacturing and strengthens its global delivery capabilities.
Also Read: Torrent Pharmaceuticals to Acquire JB Chemicals in INR 25689 Cr Deal from KKR
Piramal Pharma Expansion Encompasses Two Critical Sites:
- Riverview, Michigan: Focused on high potency APIs (HPAPIs), this site is integral to the company’s ADCelerate™ platform. A new commercial-scale suite for payload-linker development and manufacturing is scheduled for completion by late 2025.
- Lexington, Kentucky: Dedicated to sterile injectable drug products, the site will add 24,000 sq. ft. of manufacturing space, including two commercial lyophilizers, a modern sterile filling line, and a specialized lab. Completion is expected by late 2027, enabling Piramal to more than double its capacity from 104 to over 240 batches annually.
At a ceremonial groundbreaking at the Lexington site on June 25, 2025, Piramal leaders were joined by community and business leaders to celebrate this milestone in U.S. manufacturing growth.
“This strategic investment strengthens our global capabilities and prepares us for rising demand in sterile injectables and ADCs,” said Nandini Piramal, Chairperson, Piramal Pharma. “We’re prioritizing scalable, patient-focused infrastructure that enables better healthcare outcomes.”
The move aligns with the projected surge in demand – the sterile injectables market alone is forecast to exceed $20 billion by 2028. With increasing regulatory approvals, rapid R&D innovation, and the adoption of streamlined drug delivery formats, Piramal Pharma Solutions is well-positioned to meet industry expectations.
Also Read: Emcure Pharmaceuticals Posts 63 Per Cent PAT Growth in Q4FY25
“ADCs are emerging as powerful cancer therapeutics. Our expansion enables us to meet the growing complexity and scale needed in this domain,” added Peter DeYoung, CEO, Piramal Global Pharma.
Beyond infrastructure, the Lexington expansion will create 40 full-time jobs, contributing to regional economic development and reflecting Piramal’s broader commitment to U.S. onshore manufacturing and supply chain resilience.
Community and Industry Support
Lexington Mayor Linda Gorton praised the initiative, noting Lexington’s role as a growing pharmaceutical hub. IPS CEO Jim Stephanou and Commerce Lexington CEO Bob Quick echoed strong support for Piramal’s vision and investment, recognizing it as a catalyst for local biotech growth.
Piramal Pharma Solutions’ $90M investment marks a pivotal moment in its growth strategy, reinforcing its role as a trusted global partner for pharma innovation and patient-centered manufacturing.
